Product development research for global health
The Foreign Commonwealth and Development Office (FCDO) seeks expressions of interest by 23 February 2024 for research funding to develop accessible, affordable health products for use in low- and middle-income countries.
AsUse aPDP.2023@fcdo.gov.uk resultfor ofall technicalcorrespondence difficulties,relating weto havethis notcall receivedand messages sent to thesubmit emailproposals.
You originallycan publishedsend inquestions regarding this funding call and we will respond on this page. We strongly advise you to regularly check for expressionsupdates ofand interestcorrections (PDP-2023@FCDO.gov.uk).to the question and answers document:
Use
Some forquestions allthat correspondencewe relatingreceive are overlapping, particularly around eligibility. In order to thisprotect callanonymity and toavoid submitrepetition, proposals.we Ifhave yousummarised previouslyand sentamalgamated some questions orand correspondence,responses. thenWe youask shouldthat re-sendyou themonly tosend the new emailor address.follow-up questions.
We willcan respondonly guarantee to submittedrespond to questions received by midnight on Tuesday 20 February.
This funding call is focused on research and development of health products and technologies, such as medicines, vaccines, and diagnostics. Applied/system research is not prioritised in this page.call.
Overview
Submit your organisation’s expression of interest by 2pm Greenwich Mean Time (GMT) on 23 February 2024.
The Foreign, Commonwealth and Development Office (FCDO) seeks proposals for the research and development of new products to improve health outcomes for the poorest and most vulnerable in low- and middle-income countries (LMICs).
Your application should respond to at least one of the priorities:
- women and girls health
- infectious diseases of poverty
- emerging infectious diseases and diseases of epidemic potential
You should draw on the best of global health expertise, and to increase equitable and affordable access to new technologies and ensure policy uptake.
We will accept expressions of interest from non-governmental organisations and product development partnerships.
The total value of available funding is up to £130 million, the value of individual funding awards will vary.
What the fund will achieve
The fund aims to find solutions which:
- build health security for all
- support healthier and more resilient populations
- help end the preventable deaths of mothers, babies and children in low- and middle-income countries
The FCDO is increasing open scientific collaboration so the latest research, evidence and technology can help build global resilience for all, including women and girls and the most marginalised.
How to apply
Read the .
It sets out the format for expressions of interest (including annexes), to submit to PDP.2023@fcdo.gov.uk by 2pm (GMT) on 23 February 2024.
Other relevant documents:
We have also published questions and answers about this opportunity (updated, 12 February 2024):
Background information on the fund
It is likely that this competition will result in a mixture of both core organisational and project/portfolio-based funding awards. It is also likely that it will result in a mixture of funding agreement types – both accountable grants and memoranda of understanding.
For further information, refer to the call for expressions of interest document.
Contacts
If you have any questions related to this opportunity, email PDP.2023@fcdo.gov.uk.
In the interest of fairness and transparency, we will publish all questions and answers on this page before the bidding date closes.
Last updated
-
Frequently asked questions and answers document updated.
-
Frequently asked questions and answers document updated.
-
Frequently asked questions and answers document updated.
-
Frequently asked questions and answers document updated.
-
Frequently asked questions and answers document updated.
-
Frequently asked questions and answers document added.
-
There is a correction to the email address for correspondence and submitting proposals. Correspondence previously submitted should be resent to the new email address.
-
First published.